Navigation Links
Coalition for the Advancement of Medical Research Releases New White Paper, 'Catalyst for Cures: Embryonic Stem Cell Research'

- National Poll Reveals Three-Quarters of Americans Want President-Elect Obama to Deliver on Campaign Commitment to Lift Restrictions on Embryonic Stem Cell Research -

WASHINGTON, Jan. 14 /PRNewswire-USNewswire/ -- The Coalition for the Advancement of Medical Research (CAMR) today released a white paper, Catalyst For Cures: Embryonic Stem Cell Research, which outlines the views of nine of the nation's leading scientists on the promises and challenges of embryonic stem cell research. In support for the scientific community's call for reversal of the current restrictions on funding for stem cell research, the group also released the results of a national poll conducted this month for CAMR by Opinion Research Corporation indicating that nearly three-quarters (73%) of Americans believe that President-elect Obama should keep his pledge to lift existing federal restrictions on embryonic stem cell research.

Marking the 10th anniversary of the announcements by James Thomson and John Gearhart that each had successfully grown the first human pluripotent stem cell lines in culture, the White Paper proclaims that "with the knowledge gained in the past decade, stem cell research is more promising than ever."

Despite limited funding, scientists have made great strides in using these primary cells to understand what goes wrong in disease and have begun devising promising new therapies for devastating conditions, such as heart disease, spinal cord injury, and diabetes. Conversations with some of the nation's top stem cell researchers -- in academia and industry -- make clear that, with removal of limits on Federal funding, embryonic stem cell research will fulfill its promise in broader ways than originally anticipated.

"It's time for the federal government to support the broad range of stem cell research so that the greatest public benefit can be achieved on the shoulders of the last 10 years' accomplishments," said Amy Comstock Rick, president of CAMR. "We are hopeful that President-elect Obama will deliver on his campaign commitment to lift the current restrictions, and allow scientists to deliver on the promise of embryonic stem cell research."

Catalyst for Cures: Embryonic Stem Cell Research shares experts' viewpoints and assessments of embryonic stem cell research to date, and takes a bold look at where this research might lead in the coming years. Some highlights include:

"I'd be very surprised if, during the course of my scientific career, the next 20 years, we don't have much better therapies for Parkinson's disease, based on the fact that we have these hESC-derived tissues in culture," says James Thomson.

Many scientists have been studying adult stem cells and learning more about their utility and their limitations. So far, adult stem cells have only successfully been used in a very narrow area: blood system reconstitution, including bone marrow transplant, umbilical cord transplant, and peripheral blood transplant. "The argument that there are 60 to 70 diseases that can be cured with adult stem cells was never credible," says Sean Morrison, University of Michigan.

Biotech firms are revving up, focused on toxicity screening and drug development. A few are aggressively pursuing hES cell-based therapies. Big Pharma is also beginning to invest in stem cells. "Embryonic stem cells are a source of cells for predictive toxicology and drug discovery," says consultant and former Novocell executive Melissa Carpenter.

The Paper concludes that, "scientists see great promise in efforts to improve therapies for diabetes, Parkinson's disease, macular degeneration, cancer, spinal cord injuries, and heart disease. The time for removal of restrictions, expanded support, and implementation of relevant oversight guidelines is now."

The full text of Catalyst for Cures: Embryonic Stem Cell Research is available on the CAMR web site at

The following researchers and thought leaders contributed to this white paper:

Melissa K. Carpenter, Ph.D., former Vice President of Research and Development at Novocell Inc., and Director of Stem Cell Biology at Geron Corporation; George Daley, M.D., Ph.D., Harvard Medical School; Kevin C. Eggan, Ph.D., Principal Faculty, Harvard Stem Cell Institute; John P. Gearhart, M.D., Director, Institute for Regenerative Medicine at University of Pennsylvania; Ole Isacson, Dr.Med.Sci., Professor of Neurology, Harvard Medical School; Hans Keirstead, Ph.D., Associate Professor, Anatomy and Neurobiology at University of California, Irvine; Douglas A. Melton, Ph.D., Co-director of the Harvard Stem Cell Institute; Sean J. Morrison, Ph.D., Director, University of Michigan Center for Stem Cell Biology; and James Thomson, V.M.D., Ph.D., Director of Regenerative Biology at University of Wisconsin School of Medicine and Public Health.

About the Coalition for the Advancement of Medical Research

The Coalition for the Advancement of Medical Research (CAMR) -- the leading pro-cures coalition -- is comprised of nationally recognized patient organizations, universities, scientific societies, foundations, and individuals with life-threatening illnesses and disorders, advocating for the advancement of breakthrough research and technologies in regenerative medicine -- including stem cell research -- to cure disease and alleviate suffering. For more information on CAMR, visit

SOURCE Coalition for the Advancement of Medical Research
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Joins the Personalized Medicine Coalition (PMC)
2. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
3. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
4. FrontPath Health Coalition To Lead Community-wide Group in Pilot Program
5. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
6. Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story
7. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
8. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
11. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
Post Your Comments:
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, 2015 ... company developing next generation vaccines based on the ... into an exclusive worldwide licensing agreement with Astellas ... or prevention of any and all allergic diseases ... Therapeutics will receive an upfront payment of $300 ...
(Date:10/8/2015)... UK (PRWEB) , ... October 08, 2015 , ... Researchers ... literally see inside the living brain, providing a new tool to study how diseases ... is reported by Woo June Choi and Ruikang Wang of the UW Department of ...
(Date:10/8/2015)... Pa. , Oct. 8, 2015  Clarkston Consulting, ... the call for applications for the 2016 Clarkston Scholars ... a life sciences related field of study, a $10,000 ... selected Clarkston Scholar will receive exposure to the life ... in Pennsylvania Bio events over the course of the ...
(Date:10/8/2015)... , Oct. 8, 2015  Today, DuPont and ... for genome editing, jointly announced a strategic alliance. ... cross-licensed their respective patent portfolios, with DuPont receiving ... in major row crops, and non-exclusive rights in ... --> --> In ...
Breaking Biology Technology:
... Gretel ventured into the forest, they left a trail ... world, cellular phones, Global Positioning System (GPS), WiFi, and ... friends, family, and colleagues while helping us find our ... ubiquity of such devices, with few exceptions, today,s firefighters ...
... Kendle (Nasdaq: KNDL ), a leading, ... of its senior clinical development experts will present ... Association (DIA) 47th Annual Meeting, June 19-23, 2011, ... including the benefits of hybrid monitoring; finding an ...
... New Generation of the Ziehm Vision RFD Offers,Lower-Cost ... has launched a new generation of the Ziehm Vision,RFD mobile ... it to be used over an almost unlimited period,of time, ... to its mobility and significantly lower investment costs,the Ziehm Vision ...
Cached Biology Technology:
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
... VTT Technical Research Centre of Finland indicates that there is ... sold in Finland as regards fuel consumption in normal driving. ... using six used cars of different make under laboratory conditions. ... fuel consumption is significantly higher with 95E10 petrol than with ...
... A group of scientists at the Instituto Gulbenkian de Cincia, ... skeleton and organ size. The team, led by Florence Janody, ... the proteins that regulates the skeleton of the cell also ... and proliferation. Their findings have implications for cancer research, as ...
... organ in the human body that metabolizes foreign compounds such ... liver as an alarm system, researchers are starting to better ... their effects on the human body. One ... the Virginia Tech Institute of Critical Technology and Applied Science,s ...
Cached Biology News:
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
AK6 Antibody...
Biology Products: